Sahajanand Medical Technologies' initial public offering has moved into its final day of bidding with the issue showing a moderate but constructive response from investors. By the end of Day 2, the offer had been subscribed 82%, while the grey market premium hovered around 7%, indicating that sentiment remains positive, though not exuberant, ahead of the stock's expected market debut.
The Rs 475.48 crore issue is structured entirely as an offer for sale, meaning the company itself will not receive fresh capital from the IPO. Instead, the sale proceeds will accrue to existing shareholders who are trimming their stakes. That structure often places greater emphasis on valuation, earnings visibility and listing expectations, because investors are not being asked to fund expansion plans directly but to back the company's future growth trajectory and market position.
Subscription Momentum
The Day 2 subscription figure suggests the issue has found a reasonable base of demand, but not the kind of runaway response that typically accompanies the most heavily oversubscribed public offerings. In practical terms, that leaves the final bidding session important for gauging whether institutional and retail participation can accelerate enough to improve listing-day sentiment.
Market participants are also watching the category-wise response closely, as the final subscription mix often reveals where conviction is strongest. A steady close can still support a healthy debut if broader market conditions remain stable and the stock continues to command a modest premium in the unofficial market. However, a muted final-day pickup could temper expectations and keep the listing closer to intrinsic value.
GMP And Listing Watch
The grey market premium of around 7% points to limited but visible optimism. GMP is not an official indicator, but it is widely tracked by traders as a barometer of near-term listing appetite. At current levels, it implies that investors are expecting a modest premium rather than a sharp first-day surge.
That reading matters because the IPO market has become more selective. Investors are increasingly differentiating between companies with strong operating performance and those relying mainly on sectoral enthusiasm. In this case, the market appears to be balancing the company's business profile against the fact that the issue is an OFS and therefore does not directly strengthen the balance sheet.
Sahajanand Medical Technologies' appeal is also being shaped by expectations around profitability. Investors are looking at the company's reported FY26 profit growth as a key support for valuation, especially in a market where earnings momentum remains central to IPO pricing. Strong profit expansion can help justify premium valuations, but only if it is seen as durable and not merely cyclical.
What Investors Are Weighing
The final-day decision for investors is likely to hinge on three factors: subscription strength, listing premium potential and the company's medium-term earnings trajectory. For short-term traders, the question is whether the current GMP can translate into a meaningful listing gain. For longer-term investors, the more important issue is whether the company can sustain growth and defend margins after the IPO.
The broader context also matters. In a market where new listings are being scrutinised more carefully, even a well-known healthcare technology name must compete for capital against a wider set of opportunities. That means the IPO's outcome may depend less on headline size and more on the quality of demand from institutions and informed retail buyers.
As the bidding window closes, the market will be watching for the final subscription tally as the clearest signal of sentiment. A stronger-than-expected finish could reinforce the current premium and support a firmer debut. A softer close, by contrast, could leave the stock vulnerable to a subdued start despite the company's operating strengths and profit growth narrative. For now, the issue stands at an inflection point: adequately supported, but still awaiting the final verdict from investors.